PMID- 35557572
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220518
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 13
IP  - 2
DP  - 2022 Apr
TI  - Efficacy and safety of camrelizumab in combination with trastuzumab and 
      chemotherapy as the first-line treatment for patients with HER2-positive advanced 
      gastric cancer.
PG  - 548-558
LID - 10.21037/jgo-21-897 [doi]
AB  - BACKGROUND: Trastuzumab plus chemotherapy is the standard-of-care (SoC) 
      first-line therapy for HER2-positive advanced gastric cancer. Combining PD-1 
      antibody with SoC first-line therapy showed encouraging results in the 
      KEYNOTE-811 study. The retrospective study aims to evaluate the efficacy and 
      safety of SoC vs. SoC plus camrelizumab (PD-1 antibody) as a first-line treatment 
      for HER2-positive advanced gastric cancer in a real-world setting. METHODS: This 
      study included 41 patients with HER2-positive advanced gastric cancer who 
      received SoC or SoC plus camrelizumab from June 2017 to December 2020. The 
      endpoints were objective response rate (ORR), disease control rate (DCR), 
      progression-free survival (PFS), overall survival (OS), and safety. RESULTS: 
      Thirteen patients received SoC (SoC group) and 28 patients received SoC plus 
      camrelizumab (camrelizumab group). As of December 2020, the median follow-up time 
      was 10.0 months. In the camrelizumab and SoC groups, the ORRs were 75.0% and 
      46.2% (P=0.032), respectively. The DCR was 96.4% in the camrelizumab group and 
      69.2% in the SoC group (P=0.003). The median OS was 18.4 in the camrelizumab 
      group and 13.2 months in the SoC group [hazard ratio (HR) =0.343; 95% confidence 
      interval (CI): 0.151-0.783; P=0.008]. The median PFS was 3.78 in the camrelizumab 
      group and 1.74 months in the SoC group (HR =0.416; 95% CI: 0.186-0.932; P=0.027). 
      In the HER2 subgroups in the camrelizumab group, the median PFS of 
      immunohistochemistry (IHC) 3+ vs. IHC 2+ fluorescence in situ hybridization 
      (FISH) was 11.3 vs. 9.0 months (HR =1.684; 95% CI: 0.710-3.994; P=0.047). The 
      incidence rates of reactive cutaneous capillary endothelial proliferation (RCCEP) 
      (P<0.001), abnormal liver function (P=0.040), and hypothyroidism (P=0.039) 
      between the two groups were significantly different. RCCEP and hypothyroidism 
      were considered to be related to camrelizumab. CONCLUSIONS: First-line treatment 
      with camrelizumab combined with SoC showed significant clinical benefits and good 
      tolerance compared with SoC for HER2-positive advanced gastric cancer.
CI  - 2022 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Xu, Mengli
AU  - Xu M
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Meng, Xiangrui
AU  - Meng X
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Lu, Yao
AU  - Lu Y
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC9086057
OTO - NOTNLM
OT  - HER2-positive advanced gastric cancer
OT  - Retrospective study
OT  - camrelizumab
OT  - efficacy
OT  - safety
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jgo.amegroups.com/article/view/10.21037/jgo-21-897/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/14 06:01
PMCR- 2022/04/01
CRDT- 2022/05/13 18:05
PHST- 2021/12/03 00:00 [received]
PHST- 2022/03/04 00:00 [accepted]
PHST- 2022/05/13 18:05 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/14 06:01 [medline]
PHST- 2022/04/01 00:00 [pmc-release]
AID - jgo-13-02-548 [pii]
AID - 10.21037/jgo-21-897 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2022 Apr;13(2):548-558. doi: 10.21037/jgo-21-897.